CA91822J2020 - Common Stock
VBI VACCINES INC
NASDAQ:VBIV (4/18/2024, 11:55:34 AM)
0.601
-0.01 (-1.48%)
VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of infectious disease and immuno-oncology vaccines. The company is headquartered in Cambridge, Massachusetts and currently employs 190 full-time employees. The company went IPO on 2001-11-19. Through its approach to virus-like particles (VLPs), including an enveloped VLP (eVLP) platform technology, The Company develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. The firm is focused on targeting and overcoming infectious diseases, including hepatitis B (HBV), COVID-19, and coronaviruses, and cytomegalovirus (CMV), as well as cancers, including glioblastoma (GBM). Its product pipeline includes an approved vaccine and multiple late- and early-stage investigational programs. PreHevbrio is its approved vaccine for hepatitis B. Its Prophylactic Candidates for corona virus disease include VBI-2901, VBI-2905, VBI-2902, and other. VBI-1501 is its Prophylactic Candidate for cytomegalovirus. VBI-2501 is its Prophylactic Candidate for Zika virus. VBI-2601 and VBI-1901 are the therapeutic candidates for HBV and GBM.
VBI VACCINES INC
160 Second Street, Cambridge
Cambridge MASSACHUSETTS 02142
P: 16178303031
CEO: Jeffrey Baxter
Employees: 190
Website: https://www.vbivaccines.com/
VBIV stock results show that VBI Vaccines beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
These stocks have an unusual volume in today's session
It's time to dive into all of the biggest pre-market stock movers that traders will want to keep an eye on Friday morning!
Here you can normally see the latest stock twits on VBIV, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: